New Medications for Idiopathic Pulmonary Fibrosis

Two new drugs have been proven in large international studies to significantly slow the progress of idiopathic pulmonary fibrosis (IPF). Pirfenidone, a novel antifibrotic and anti-inflammatory agent and nintedanib, a tyrosine kinase inhibitor, have both been FDA approved for the treatment of IPF.13 Before approval of these two agents, no treatment for IPF had been available and life expectancy post-diagnosis was no more than 3–5 years.14


Continue Reading